Experimental drug findings pave way for clinical trial to target cancer’s elusive growth switch

Researchers at the Francis Crick Institute and Vividion Therapeutics have identified chemical compounds that can precisely block the interaction between the major cancer-driving gene RAS and a key pathway for tumor growth.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup